7-117590442-A-C
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PM2PP3PP5_Very_Strong
The NM_000492.4(CFTR):c.1766+3A>C variant causes a splice region, intron change. The variant allele was found at a frequency of 0.000000691 in 1,447,328 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000492.4 splice_region, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.1766+3A>C | splice_region_variant, intron_variant | Intron 13 of 26 | ENST00000003084.11 | NP_000483.3 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.91e-7 AC: 1AN: 1447328Hom.: 0 Cov.: 30 AF XY: 0.00 AC XY: 0AN XY: 719824
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Cystic fibrosis Pathogenic:5
Variant summary: CFTR c.1766+3A>C, also reported as c.1898+3A>C, alters a conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Several computational tools predict a significant impact on normal splicing: One predicts the variant abolishes a 5' splicing donor site. Two predict the variant weakens a 5' donor site. At least one publication reports experimental evidence that this variant affects mRNA splicing in an in vitro minigene assay in a eukaryotic cell line, demonstrating near total in frame skipping of exon 13 [exon "12" by alternate nomenclature] (example, Fernandez Alanis_2012). The skipped in frame exon contains a known Pathogenic variant, p.Pro574His, and its loss in the transcript is therefore predicted to be deleterious. The variant was absent in 249012 control chromosomes. c.1766+3A>C has been reported in the simple heterozygous [2nd allele not specified], presumed compound heterozygous, or homozygous state in the literature and CFTR-France database in multiple individuals affected with Cystic Fibrosis or congenital bilateral absence of the vas deferens (example, Kinnunen_2005, Mercier_1995, Naguib_2007, Trujillano_2013, CFTR-France). These data indicate that the variant is likely to be associated with disease. The following publications have been ascertained in the context of this evaluation (PMID: 22362925, 16051530, 7581406, 16837250, 23687349). ClinVar contains an entry for this variant (Variation ID: 53378). Based on the evidence outlined above, the variant was classified as pathogenic. -
The variant is not observed in the gnomAD v2.1.1 dataset. In silico tools predict the variant to alter splicing and produce an abnormal transcript (SpliceAI: 0.78). The variant has been reported at least twice as pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000053378). Therefore, this variant is classified as Likely pathogenic according to the recommendation of ACMG/AMP guideline. -
This sequence change falls in intron 13 of the CFTR gene. It does not directly change the encoded amino acid sequence of the CFTR protein. RNA analysis indicates that this variant induces altered splicing and likely results in a shortened protein product. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with clinical features of CFTR-related conditions (PMID: 7581406, 16051530). This variant is also known as 1898+3 A>C. ClinVar contains an entry for this variant (Variation ID: 53378). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in skipping of exon 13, but is expected to preserve the integrity of the reading-frame (PMID: 22362925). This variant disrupts a region of the CFTR protein in which other variant(s) (p.Asp579Gly) have been determined to be pathogenic (PMID: 7544319, 15463898, 26494713, 27738188, 27812499). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. -
- -
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at